Albumin-bilirubin score reflects the extent of liver fibrosis in chronic hepatitis C patients treated with direct-acting antivirals

Table 2 Patients’ laboratory profile, including albumin-bilirubin score, before and after direct-acting antiviral treatment, median ± interquartile range

	Pre-treatment median	Post-treatment	Statistical value	P value1
AFP	5.38 ± 5.00	5.3 ± 4.0	-3.3	0.001
ALBI	-2.51 ± 0.65	-2.62 ± 0.62	-3.77	< 0.001
Albumin2	36.77 ± 5.36	37.66 ± 5.60	-3	< 0.001
ALP	88.5 ± 42.5	78 ± 32	-4.7	< 0.001
ALT	46.5 ± 49.0	18 ± 13	-12.27	< 0.001
AST	37.5 ± 32.0	21 ± 11	-11.34	< 0.001
Hemoglobin	13.65 ± 2.3	13.3 ± 2.8	-3.5	< 0.001
INR	1.10 ± 0.10	1.1 ± 0.2	-1.5	0.132
Platelets2	231.68 ± 88.75	232.65 ± 85.38	-1.4	0.153
Total bilirubin	10.7 ± 7.8	9.1 ± 7.3	-0.298	0.760
WBC	5.91 ± 2.39	6.13 ± 2.99	-2.9	0.003

¹Wilcoxon signed ranks test.

²Presented as mean ± SD and were compared with paired t-test.

AFP: Alpha fetoprotein; ALBI: Albumin-bilirubin; ALP: Alkaline phosphatase; ALT: Alanine transaminase; INR: International normalized ratio; WBC: White blood count.